Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study

被引：0
|
作者：
Qu, Xin
Chen, Xian
Li, Yong
Liu, Li-rong
Qu, Yan-chun
Hou, Fang-fang
Li, Wen-zhu
Liu, Yi-hong
Zhu, Yan-juan
Zhang, Haibo
机构：
[1] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China
[2] Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China
[3] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Prov Hosp Tradit Chinese Med, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS220
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Bao, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
    Lee, Choong-kun
    Jung, Minkyu
    Park, Sejung
    Kwon, Woo Sun
    Kim, Kyoo Hyun
    Hong, Moonki
    Kim, Hyunwook
    Kim, Hyo Song
    Chung, Hyun Cheol Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 374 - 374
  • [3] Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
    Ahn, Daniel H.
    Ridinger, Maya
    Cannon, Timothy L.
    Mendelsohn, Lawrence
    Starr, Jason S.
    Hubbard, Joleen M.
    Kasi, Anup
    Barzi, Afsaneh
    Samuelsz, Errin
    Karki, Anju
    Subramanian, Ramanand A.
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [4] SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study
    Zhang, Pei
    Li, Xiaofen
    Wang, Xin
    Yang, Yu
    Wang, Jianfei
    Cao, Dan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [5] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
    Liu, Dechun
    Yan, Tao
    Zhang, Qian
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S89 - S90
  • [6] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
    Bennouna, Jaafar
    Borg, Christophe
    Delord, Jean-Pierre
    Husseini, Faress
    Trillet-Lenoir, Veronique
    Faroux, Roger
    Francois, Eric
    Ychou, Marc
    Goldwasser, Francois
    Bouche, Olivier
    Senellart, Helene
    Kraemer, Sandrine
    Douillard, Jean-Yves
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
  • [7] A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer
    Wang, Guojun
    Ye, Yanwei
    Zhang, Xiefu
    Liu, Hongxiang
    Song, Junmin
    MEDICAL ONCOLOGY, 2015, 32 (05)
  • [8] A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer
    Guojun Wang
    Yanwei Ye
    Xiefu Zhang
    Hongxiang Liu
    Junmin Song
    Medical Oncology, 2015, 32
  • [9] Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
    Cheng, Q.
    Jiang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1468 - S1469
  • [10] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
12345